Literature DB >> 26772776

Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation.

Wen-Shin Lee1,2, Katalin Erdelyi1, Csaba Matyas1,3, Partha Mukhopadhyay1, Zoltan V Varga1, Lucas Liaudet4, György Haskú5, Daniela Čiháková6, Raphael Mechoulam7, Pal Pacher1.   

Abstract

Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a nonpsychoactive constituent of marijuana that exerts antiinflammatory effects independent of classical cannabinoid receptors. Recently, 80 clinical trials have investigated the effects of CBD in various diseases from inflammatory bowel disease to graft versus host disease. CBD-based formulations are used for the management of multiple sclerosis in numerous countries, and CBD also received U.S. Food and Drug Administration approval for the treatment of refractory childhood epilepsy and glioblastoma multiforme. Herein, using a well-established mouse model of experimental autoimmune myocarditis (EAM) induced by immunization with cardiac myosin emmulsified in adjuvant resulting in T cell-mediated inflammation, cardiomyocyte cell death, fibrosis and myocardial dysfunction, we studied the potential beneficial effects of CBD. EAM was characterized by marked myocardial T-cell infiltration, profound inflammatory response and fibrosis (measured by quantitative real-time polymerase chain reaction, histology and immunohistochemistry analyses) accompanied by marked attenuation of both systolic and diastolic cardiac functions measured with a pressure-volume conductance catheter technique. Chronic treatment with CBD largely attenuated the CD3+ and CD4+ T cell-mediated inflammatory response and injury, myocardial fibrosis and cardiac dysfunction in mice. In conclusion, CBD may represent a promising novel treatment for managing autoimmune myocarditis and possibly other autoimmune disorders and organ transplantation.

Entities:  

Year:  2016        PMID: 26772776      PMCID: PMC5004721          DOI: 10.2119/molmed.2016.00007

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  51 in total

1.  Cannabidiol-induced lymphopenia does not involve NKT and NK cells.

Authors:  B Ignatowska-Jankowska; M Jankowski; W Glac; A H Swiergel
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

2.  Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy.

Authors:  G Christian Baldeviano; Jobert G Barin; Monica V Talor; Sachin Srinivasan; Djahida Bedja; Dongfeng Zheng; Kathleen Gabrielson; Yoichiro Iwakura; Noel R Rose; Daniela Cihakova
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

Review 3.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.

Authors:  Karen Bedard; Karl-Heinz Krause
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

4.  Nitric oxide synthase 2 is required for conversion of pro-fibrogenic inflammatory CD133(+) progenitors into F4/80(+) macrophages in experimental autoimmune myocarditis.

Authors:  Przemyslaw Blyszczuk; Corrine Berthonneche; Silvia Behnke; Marcel Glönkler; Holger Moch; Thierry Pedrazzini; Thomas F Lüscher; Urs Eriksson; Gabriela Kania
Journal:  Cardiovasc Res       Date:  2012-10-22       Impact factor: 10.787

5.  Fatal eosinophilic myocarditis develops in the absence of IFN-γ and IL-17A.

Authors:  Jobert G Barin; G Christian Baldeviano; Monica V Talor; Lei Wu; SuFey Ong; DeLisa Fairweather; Djahida Bedja; Natalie R Stickel; Jillian A Fontes; Ashley B Cardamone; Dongfeng Zheng; Kathleen L Gabrielson; Noel R Rose; Daniela Ciháková
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

6.  Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3.

Authors:  Urs Eriksson; Michael O Kurrer; Nicole Schmitz; Stephan C Marsch; Adriano Fontana; Hans-Pietro Eugster; Manfred Kopf
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

7.  Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats.

Authors:  Pablo Nakagawa; Yunhe Liu; Tang-Dong Liao; Xiaojuan Chen; Germán E González; Kevin R Bobbitt; Derek Smolarek; Ed L Peterson; Ross Kedl; Xiao-Ping Yang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-24       Impact factor: 4.733

Review 8.  The heart of the matter: protection of the myocardium from T cells.

Authors:  Andrew H Lichtman
Journal:  J Autoimmun       Date:  2013-06-28       Impact factor: 7.094

9.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis.

Authors:  Urs Eriksson; Michael O Kurrer; Ivo Sonderegger; Giandomenica Iezzi; Anna Tafuri; Lukas Hunziker; Shinobu Suzuki; Kurt Bachmaier; Roland M Bingisser; Josef M Penninger; Manfred Kopf
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more
  17 in total

1.  Pharmacological Properties of the Plant-Derived Natural products Cannabinoids and Implications for Cardiovascular Health.

Authors:  Luca Liberale; Fabrizio Montecucco; Federico Carbone
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 3.  Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Authors:  Attila Oláh; Zoltán Szekanecz; Tamás Bíró
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

4.  Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury.

Authors:  Yuping Wang; Partha Mukhopadhyay; Zongxian Cao; Hua Wang; Dechun Feng; György Haskó; Raphael Mechoulam; Bin Gao; Pal Pacher
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

Review 5.  Immune Responses Regulated by Cannabidiol.

Authors:  James M Nichols; Barbara L F Kaplan
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

6.  Akt inhibitor deguelin aggravates inflammation and fibrosis in myocarditis.

Authors:  Shanshan Li; Yue Wang; Chunming Zhao; Meixiang Zhang; Wei Wang; Xiaowei Yu; Jiao Huang; Zhao Wang; Bo Zhu; Chengqian Yin; Hongxing Cai
Journal:  Iran J Basic Med Sci       Date:  2019-11       Impact factor: 2.699

Review 7.  Cannabis Sativa Revisited-Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis.

Authors:  Anca Raluca Dinu; Alexandru Florin Rogobete; Tiberiu Bratu; Sonia Elena Popovici; Ovidiu Horea Bedreag; Marius Papurica; Lavinia Melania Bratu; Dorel Sandesc
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

Review 8.  T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation.

Authors:  E Stephenson; K Savvatis; S A Mohiddin; F M Marelli-Berg
Journal:  Br J Pharmacol       Date:  2016-10-04       Impact factor: 8.739

Review 9.  The nephrologist's guide to cannabis and cannabinoids.

Authors:  Joshua L Rein
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

Review 10.  Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure.

Authors:  J A Garza-Cervantes; M Ramos-González; O Lozano; C Jerjes-Sánchez; G García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2020-10-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.